- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04436133
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
A Randomized, Blind, and Positive Control Design to Evaluate the Immunization Efficacy of 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-26 Years
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Guangxi
-
Liuzhou, Guangxi, China
- Liucheng Center for Disease Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chinese women aged 18-26 who can provide legal identification;
- The subject has the ability to understand the research procedure and sign an informed consent;
- Subjects have the ability to read, understand, fill out diary cards/contact cards and other research application forms and promise to participate in regular follow-up as required by the research;
- No previous history of HPV vaccination, no participation in HPV vaccine clinical trials, and no plans to receive HPV vaccine during the study period; The subject was not breastfeeding or pregnant (negative urine pregnancy test), did not have a birth plan within 7 months of enrollment; and from day 1 of the last menstrual cycle to day 0 of the study, did not have sex with men or with men Effective contraception was used during sex and no contraceptive failures occurred (examples of contraceptive failure include male condom rupture during sex). And agreed to continue to take effective contraceptive measures within the first 7 months after participating in the study (effective contraceptive measures include: oral contraceptives, hormone patches, intrauterine devices, condoms, cervical caps, etc.).
First dose exclusion criteria:
- Previous history of cervical lesions (such as abnormal cervical cancer screening, history of CIN disease) or history of hysterectomy surgery (vaginal or total hysterectomy) or history of pelvic radiation therapy; previous history of external genital diseases (such as vulvar epithelium) Neoplasia, intraepithelial neoplasia and genital warts, etc.);
- Previous history of severe allergic reactions requiring medical intervention for any vaccine or drug (including yeast) (eg: anaphylactic shock, allergic throat edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction) Wait);
- Immune function is impaired or has been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile Rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;
- Long-term treatment with immunosuppressive agents, such as: long-term (more than 2 weeks in a row) treatment with glucocorticoids (eg, prednisone or similar drugs);
- Receive any immunoglobulin or blood products within 3 months before vaccination, or plan to receive such products before the 7th month of the study;
- Received inactivated vaccine or recombinant vaccine within 14 days before vaccination, or received any live vaccine within 28 days;
- Loss of spleen or functional spleen, and removal of spleen or spleen caused by any situation;
- Has been diagnosed with a disease that may interfere with the progress or completion of the study, such as: suffering from severe cardiovascular disease (pulmonary heart disease, pulmonary edema), severe liver and kidney disease, diabetes with complications, etc.; or has been diagnosed with Infectious diseases, such as: active tuberculosis, hepatitis B, hepatitis C, etc.;
- A history of convulsions, epilepsy, encephalopathy, mental illness, family history of mental illness, etc.;
- There are thrombocytopenia or other coagulation disorders that can be contraindications to intramuscular injection; 11.3 days before the vaccination, suffering from acute disease or in the acute onset of chronic disease or using antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, cetaxidine Tirizine, etc.);
12.Body temperature before inoculation≥37.3℃(armpit body temperature); 13. People who have a systolic blood pressure ≥140mmHg and/or a diastolic blood pressure ≥90mmHg before enrollment; 14. Participate or plan to participate in other clinical trials (drugs, vaccines and medical devices) during the study; 15. Plan to move out of the local area before the end of the study or leave the area for a long time during the scheduled study visit;
Exclusion criteria for second and third doses of vaccination:
- Before vaccination (the day of vaccination), pregnant or urine pregnancy test (HCG) is positive; Note: If the subject chooses to terminate the pregnancy, at least 6 weeks after the end of pregnancy and the urine pregnancy test is negative on the day before the vaccination, or the medical certificate of termination of pregnancy issued after the end of pregnancy indicates that HCG levels have returned to normal levels, you can continue Vaccination; if you choose to continue pregnancy, you will not be vaccinated for subsequent doses.
- Newly discovered or newly occurred conditions that meet the first dose exclusion criteria (except Articles 1 and 13);
- Other serious adverse events: The researcher decides whether to terminate the test vaccination according to his treatment needs;
- The investigator assessed any other reasons why the vaccination for the trial should be terminated.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: vaccine group
|
Inject vaccine produced by ChinaVaccineSerum, containing HPV antigen protein, 270μg/1ml per bottle
|
Active Comparator: Positive control group
|
Inject Gardasil 9 , containing HPV antigen protein, 270μg/0.5ml
per bottle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anti-HPV neutralizing antibodies GMT
Time Frame: 30 days after full immunization
|
30 days after full immunization
|
|
Anti-HPV neutralizing antibody positive conversion rate(after full immunization 30 days)
Time Frame: 30 days after full immunization
|
30 days after full immunization
|
|
Collect all SAEs
Time Frame: through study completion, an average of 13 months
|
Vaccine-related and unrelated
|
through study completion, an average of 13 months
|
Collect AEs incidence
Time Frame: Within 30 minutes of injection
|
Vaccine-related and unrelated
|
Within 30 minutes of injection
|
Collect AEs incidence
Time Frame: Within 30 days after inoculation
|
All AEs: incidence of AEs related to vaccines and unrelated The rate of Solicited for AE Non-collective AEs: incidence of AEs related to vaccines and unrelated AE level 3 and above: incidence of vaccine-related and unrelated AEs |
Within 30 days after inoculation
|
collect AEs leading subject to withdrawal
Time Frame: through study completion, an average of 13months
|
Incidence of vaccine-related and unrelated AEs
|
through study completion, an average of 13months
|
collect All pregnancy conditions and pregnancy outcomes
Time Frame: through study completion, an average of 13 months
|
collect pregnant woman Anti-HPV neutralizing antibody positive conversion rate and Anti-HPV neutralizing antibodies GMT
|
through study completion, an average of 13 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GXIRB2020-0036
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV Infection
-
Lee's Pharmaceutical LimitedUnknownCervical HPV-16 and / or HPV-18 InfectionChina
-
Sinocelltech Ltd.RecruitingHPV Infection Vaccine Safety SCT1000China
-
Ulla Bonde van ZwolUniversity of Southern Denmark; Region of Southern Denmark; MCM Vaccines B.V.Unknown
-
PDS Biotechnology Corp.CompletedHigh-risk HPV Infection and Biopsy-proven CIN1United States
-
Capital Medical UniversityUnknown
-
Kenya Medical Research InstituteMerck Sharp & Dohme LLC; University of WashingtonCompletedHPV Infection | HPV Vaccine | HIV-1-infectionKenya
-
Merck Sharp & Dohme LLCCompletedHPV Infections
-
University of Alabama at BirminghamCompleted
-
Merck Sharp & Dohme LLCSuspended
-
University of WashingtonActive, not recruiting
Clinical Trials on Biological/Vaccine: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
-
National Vaccine and Serum Institute, ChinaSichuan Center for Disease Control and Prevention; Hunan Provincial Center... and other collaboratorsRecruitingHPV-Related Carcinoma | HPV InfectioNChina
-
National Vaccine and Serum Institute, ChinaGuangxi Center for Disease Control and Prevention; Simoon Record Pharma Information... and other collaboratorsCompleted
-
Beijing Chaoyang District Centre for Disease Control...Unknown
-
Shanghai Bovax Biotechnology Co., Ltd.RecruitingCervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AISChina
-
Shanghai Bovax Biotechnology Co., Ltd.TerminatedCervical Cancer | CIN1 | CIN2 | CIN3 | Genital Wart | AIS | Vain I | Vain III | Vin I | Vin II | Vin III | VAIN - Vaginal Intraepithelial Neoplasia 2China
-
National Vaccine and Serum Institute, ChinaLanzhou Institute of Biological Products Co., LtdNot yet recruitingNorwalk Gastroenteritis | Norovirus Infections
-
Medical College of WisconsinMerck Sharp & Dohme LLCRecruitingChronic Kidney Diseases | Kidney TransplantUnited States
-
National Cancer Institute (NCI)Active, not recruitingHuman Papillomavirus-Related Cervical CarcinomaCosta Rica
-
PATHNational Institute of Hygiene and Epidemiology, VietnamCompleted